These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36207653)

  • 1. Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
    Kahn RM; Ahsan MD; Chapman-Davis E; Holcomb K; Nitecki R; Rauh-Hain JA; Fowlkes RK; Tubito F; Pires M; Christos PJ; Tkachuk K; Krinsky H; Sharaf RN; Offit K; Lipkin S; Frey MK
    Fam Cancer; 2023 Apr; 22(2):127-133. PubMed ID: 36207653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.
    Frey MK; Kahn RM; Chapman-Davis E; Tubito F; Pires M; Christos P; Anderson S; Mukherjee S; Jordan B; Blank SV; Caputo TA; Sharaf RN; Offit K; Holcomb K; Lipkin S
    J Clin Oncol; 2020 May; 38(13):1389-1397. PubMed ID: 31922918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review.
    Afaya A; Kim SW; Park HS; Lim MC; Jung MS; Nam EJ; Park JS; Jeong J; Ryu JM; Kim J; Kim J; Kim M; Jin J; Han J; Kim SY; Park SY; Katapodi MC; Kim S;
    Fam Cancer; 2024 Jun; 23(2):121-132. PubMed ID: 38662264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of Cascade Genetic Testing for Hereditary Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis.
    Ahsan MD; Chandler IR; Min S; Grant B; Primiano M; Greenwald J; Soussana TN; Baltich Nelson B; Thomas C; Chapman-Davis E; Sharaf RN; Frey MK
    Clin Obstet Gynecol; 2024 Dec; 67(4):702-710. PubMed ID: 39431491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
    Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Streamlined Genetic Education and Cascade Testing in Men from Hereditary Breast Ovarian Cancer Families: A Randomized Trial.
    Grisham C; Peshkin BN; Sorgen L; Isaacs C; Ladd MK; Jacobs A; Binion S; Tynan M; Kuchinsky E; Friedman S; Taylor KL; Graves K; O'Neill S; Kim D; Schwartz MD
    Public Health Genomics; 2024; 27(1):100-109. PubMed ID: 39173603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
    Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
    Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system.
    Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
    Clin Genet; 2022 Mar; 101(3):324-334. PubMed ID: 34927729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic counselors' perspectives on population-based screening for BRCA-related hereditary breast and ovarian cancer and Lynch syndrome.
    De Simone LM; Arjunan A; Vogel Postula KJ; Maga T; Bucheit LA
    J Genet Couns; 2021 Feb; 30(1):158-169. PubMed ID: 32562467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
    Rowley SM; Mascarenhas L; Devereux L; Li N; Amarasinghe KC; Zethoven M; Lee JEA; Lewis A; Morgan JA; Limb S; Young MA; James PA; Trainer AH; Campbell IG
    Genet Med; 2019 Apr; 21(4):913-922. PubMed ID: 30254378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
    Bellcross CA
    Obstet Gynecol Clin North Am; 2022 Mar; 49(1):117-147. PubMed ID: 35168766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia.
    Petelin L; James PA; Trainer AH
    Intern Med J; 2018 Oct; 48(10):1269-1272. PubMed ID: 30288903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCAShare-Assessment of an animated digital message for intrafamilial communication of pathogenic variant positive test results: A feasibility study.
    Aeilts AM; Carpenter KM; Hovick SR; Byrne L; Shoben AB; Senter L
    J Genet Couns; 2023 Apr; 32(2):475-485. PubMed ID: 36426678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.
    Steffen LE; Du R; Gammon A; Mandelblatt JS; Kohlmann WK; Lee JH; Buys SS; Stroup AM; Campo RA; Flores KG; Vicuña B; Schwartz MD; Kinney AY
    Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1772-1780. PubMed ID: 28971986
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of Implementing B-RST
    Wernke K; Bellcross C; Gabram S; Ali N; Stanislaw C
    Clin Breast Cancer; 2019 Aug; 19(4):e547-e555. PubMed ID: 31005475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
    Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing.
    Frey MK; Ahsan MD; Badiner N; Lin J; Narayan P; Nitecki R; Rauh-Hain JA; Moss H; Fowlkes RK; Thomas C; Bergeron H; Christos P; Levi SR; Blank SV; Holcomb K; Cantillo E; Sharaf RN; Lipkin S; Offit K; Chapman-Davis E
    Cancer; 2022 Dec; 128(24):4241-4250. PubMed ID: 36305018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facilitated cascade testing (FaCT): a randomized controlled trial.
    Nitecki R; Moss HA; Watson CH; Urbauer DL; Melamed A; Lu KH; Lipkin SM; Offit K; Rauh-Hain JA; Frey MK
    Int J Gynecol Cancer; 2021 May; 31(5):779-783. PubMed ID: 33443030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.